Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Bcyc are up

<< Previous

Bullboard Posts

Next >>

Comment by Wino115on Oct 07, 2021 5:51pm

127 Views

Post# 33986547

RE:RE:RE:Bcyc are up

just guessing it must be close to or causing death?

qwerty22 wrote:
Just as an example of the slipperiness of biotech sometimes. The first toxicity statement they make is this.

" In addition, and in contrast to the toxicities observed with MedImmune’s EphA2 antibody-drug conjugate (ADC) MEDI-547, Bicycle has observed no signs of coagulopathy to date."

Which makes it sound like things are pretty good.

Next statement

"Some mild and transient neutropenia was observed at 8.5mg/m2 every week, although this did not constitute a DLT. At 10mg/m2 every other week, two DLTs were observed (Grade 3 fatigue and Grade 3 pneumonitis)."

Also not too bad, sets where the MTD might be.

Final statement.

"The most common Grade 3 and above events were neutropenia, anemia and pneumonitis and there were two Grade 5 events: tumor lysis syndrome and renal failure caused by GI-related dehydration."

Quick quiz : Anybody know what a grade 5 event is?

qwerty22 wrote:

just looking at the BT5528 data. The efficacy is really nice (hopefully they get that). Some red flags in the safety data. So the market cap is up $400-$500 mil over 1and 1/2 months. I think it started with an analyst upgrade but it looks like this data has managed to keep those gains and add to them. I don't know if as people digest that safety data there won't be some negativity.

qwerty22 wrote: On Ph1 data. They've been going up for a month of so and a nice jump on this news. They even did a short halt.

https://stockhouse.com/news/press-releases/2021/10/07/bicycle-therapeutics-announces-interim-bt5528-phase-i-clinical-trial-results-and